Fiche société
Find Therapeutics
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications2liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| FTX-101This is a Phase 1, first-in-human (FIH), single-center, randomized, double-blind, placebo-controlled study in healthy male subjects. The study will include the following 2 parts: * Part A: Single Ascending Dose (SAD) in healthy male subjects * Part B: Multiple Ascending Dose (MAD) in healthy male subjects | SEP | Phase 1 | À vérifier | United States | À vérifier |
| FTX-101This is a Phase 1, first-in-human (FIH), single-center, randomized, double-blind, placebo-controlled study in healthy male subjects. The study will include the following 2 parts: * Part A: Single Ascending Dose (SAD) in healthy male subjects * Part B: Multiple Ascending Dose (MAD) in healthy male subjects | SEP | Phase 1 | À vérifier | United States | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| FTX-101 | SEP | Phase 1 | NCT06617546 | SAD and MAD Study of FTX-101 in Healthy Male Subjects | TERMINATED |
Publications
2| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| FTX-101 | Disruption of Plexin-A1 signaling by FTX-101: mode of action and effect on oligodendrocyte biology. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | ||
| FTX-101 | Neuropilins in Multiple Sclerosis: Dual Roles of NRP-1 in Neuroinflammation and Neuroprotection. | Neuromolecular medicine |